Ekso Bionics Holdings, Inc. (EKSO)
USD 0.63
(-11.99%)
USD 0.63
(-11.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 24.19 Million USD | 13.96% |
| 2022 | 21.77 Million USD | 5.8% |
| 2021 | 20.57 Million USD | 14.78% |
| 2020 | 17.92 Million USD | -23.39% |
| 2019 | 23.4 Million USD | -25.41% |
| 2018 | 31.37 Million USD | -5.94% |
| 2017 | 33.35 Million USD | 8.54% |
| 2016 | 30.72 Million USD | 35.13% |
| 2015 | 22.74 Million USD | 23.9% |
| 2014 | 18.35 Million USD | 160314.3% |
| 2013 | 11.44 Thousand USD | -99.92% |
| 2012 | 14.68 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.97 Million USD | -4.51% |
| 2024 Q3 | 4.84 Million USD | -2.49% |
| 2024 Q1 | 5.2 Million USD | -10.5% |
| 2023 Q3 | 5.38 Million USD | -17.6% |
| 2023 Q4 | 5.81 Million USD | 8.0% |
| 2023 FY | 24.81 Million USD | 13.96% |
| 2023 Q1 | 6.44 Million USD | 5.46% |
| 2023 Q2 | 6.53 Million USD | 1.4% |
| 2022 Q4 | 6.11 Million USD | 14.49% |
| 2022 FY | 21.77 Million USD | 5.8% |
| 2022 Q1 | 5.44 Million USD | -21.83% |
| 2022 Q3 | 5.34 Million USD | 9.65% |
| 2022 Q2 | 4.87 Million USD | -10.58% |
| 2021 Q4 | 6.96 Million USD | 51.59% |
| 2021 Q3 | 4.59 Million USD | -0.95% |
| 2021 Q2 | 4.64 Million USD | 6.08% |
| 2021 Q1 | 4.37 Million USD | 0.37% |
| 2021 FY | 20.57 Million USD | 14.78% |
| 2020 Q2 | 4.1 Million USD | -24.2% |
| 2020 Q4 | 4.35 Million USD | 7.74% |
| 2020 Q3 | 4.04 Million USD | -1.51% |
| 2020 FY | 17.92 Million USD | -23.39% |
| 2020 Q1 | 5.41 Million USD | 15.45% |
| 2019 Q3 | 5.56 Million USD | -16.49% |
| 2019 Q1 | 6.51 Million USD | -2.16% |
| 2019 Q2 | 6.65 Million USD | 2.27% |
| 2019 Q4 | 4.69 Million USD | -15.59% |
| 2019 FY | 23.4 Million USD | -25.41% |
| 2018 Q2 | 8.14 Million USD | -13.3% |
| 2018 FY | 31.37 Million USD | -5.94% |
| 2018 Q4 | 6.65 Million USD | -7.24% |
| 2018 Q3 | 7.17 Million USD | -11.98% |
| 2018 Q1 | 9.39 Million USD | 5.96% |
| 2017 Q3 | 7.62 Million USD | -8.97% |
| 2017 Q4 | 8.87 Million USD | 16.31% |
| 2017 FY | 33.35 Million USD | 8.54% |
| 2017 Q1 | 8.49 Million USD | 10.0% |
| 2017 Q2 | 8.37 Million USD | -1.37% |
| 2016 Q2 | 7.59 Million USD | -6.65% |
| 2016 FY | 30.72 Million USD | 35.13% |
| 2016 Q4 | 7.72 Million USD | 6.22% |
| 2016 Q3 | 7.26 Million USD | -4.34% |
| 2016 Q1 | 8.14 Million USD | 26.05% |
| 2015 Q1 | 4.49 Million USD | -16.94% |
| 2015 FY | 22.74 Million USD | 23.9% |
| 2015 Q4 | 6.45 Million USD | 14.32% |
| 2015 Q3 | 5.64 Million USD | -7.95% |
| 2015 Q2 | 6.13 Million USD | 36.5% |
| 2014 Q3 | 4.21 Million USD | -3.33% |
| 2014 Q2 | 4.35 Million USD | -0.34% |
| 2014 Q1 | 4.37 Million USD | 72574.43% |
| 2014 FY | 18.35 Million USD | 160314.3% |
| 2014 Q4 | 5.41 Million USD | 28.53% |
| 2013 FY | 11.44 Thousand USD | -99.92% |
| 2013 Q4 | 6015.00 USD | 319.75% |
| 2013 Q1 | 3833.00 USD | 147.29% |
| 2013 Q2 | 23.16 Thousand USD | 504.3% |
| 2013 Q3 | 1433.00 USD | -93.81% |
| 2012 Q3 | 1200.00 USD | -75.3% |
| 2012 FY | 14.68 Million USD | 0.0% |
| 2012 Q2 | 4858.00 USD | 0.0% |
| 2012 Q4 | 1550.00 USD | 29.17% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 104.27 Million USD | 76.8% |
| AngioDynamics, Inc. | 252.41 Million USD | 90.416% |
| AtriCure, Inc. | 327.05 Million USD | 92.603% |
| Avinger, Inc. | 18.63 Million USD | -29.794% |
| Azenta, Inc. | 336.26 Million USD | 92.806% |
| BioLife Solutions, Inc. | 117.57 Million USD | 79.425% |
| The Cooper Companies, Inc. | 1.82 Billion USD | 98.674% |
| Daxor Corporation | 1.28 Million USD | -1789.162% |
| Femasys Inc. | 15.2 Million USD | -59.148% |
| GlucoTrack, Inc. | 7.1 Million USD | -240.526% |
| Harvard Bioscience, Inc. | 58.58 Million USD | 58.705% |
| Hologic, Inc. | 1.34 Billion USD | 98.202% |
| ICU Medical, Inc. | 717.04 Million USD | 96.626% |
| Intuitive Surgical, Inc. | 2.96 Billion USD | 99.183% |
| KORU Medical Systems, Inc. | 26.1 Million USD | 7.342% |
| LeMaitre Vascular, Inc. | 90.33 Million USD | 73.221% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 20372.524% |
| Innovative Eyewear, Inc. | -119.32 Thousand USD | 20372.524% |
| Masimo Corporation | 867 Million USD | 97.21% |
| Microbot Medical Inc. | 9.85 Million USD | -145.469% |
| Meihua International Medical Technologies Co., Ltd. | 18.42 Million USD | -31.33% |
| Merit Medical Systems, Inc. | 459.92 Million USD | 94.74% |
| Nephros, Inc. | 9.78 Million USD | -147.251% |
| NovoCure Limited | 613.92 Million USD | 96.06% |
| NEXGEL, Inc. | 4.09 Million USD | -490.601% |
| NEXGEL, Inc. | 4.09 Million USD | -490.601% |
| Singular Genomics Systems, Inc. | 102.24 Million USD | 76.34% |
| OraSure Technologies, Inc. | 125.34 Million USD | 80.7% |
| Pro-Dex, Inc. | 7.37 Million USD | -227.88% |
| Pulse Biosciences, Inc. | 43.57 Million USD | 44.483% |
| Predictive Oncology Inc. | 15.22 Million USD | -58.843% |
| Precision Optics Corporation, Inc. | 8.52 Million USD | -183.862% |
| QuidelOrtho Corporation | 1.35 Billion USD | 98.215% |
| Repligen Corporation | 261.12 Million USD | 90.736% |
| Sanara MedTech Inc. | 61.12 Million USD | 60.425% |
| STAAR Surgical Company | 224.55 Million USD | 89.227% |
| Sharps Technology, Inc. | 10.12 Million USD | -138.885% |
| Utah Medical Products, Inc. | 13.26 Million USD | -82.422% |
| DENTSPLY SIRONA Inc. | 1.79 Billion USD | 98.652% |
| Jin Medical International Ltd. | 3.91 Million USD | -517.5% |